Cefpodoxime Proxetil

Cefpodoxime proxetil is an oral broad-spectrum third-generation cephalosporin. After entering the body, it is hydrolyzed into cefpodoxime by non-specific esterases to exert antibacterial effects. It is effective against both Gram-positive and Gram-negative bacteria. The mechanism of action of this product is to achieve a bactericidal effect by inhibiting the biosynthesis of microbial cell walls. This product is stable to β-lactamase, so many β-lactamase-producing microorganisms that are resistant to penicillin and cephalosporins are still sensitive to this product. This product is ineffective against certain ultra-extended-spectrum β-lactamases. Both in vitro and clinical infection studies have confirmed that this product is active against most of the following microorganisms: 1 Aerobic Gram-positive microorganisms: Staphylococcus aureus (including penicillinase-producing strains, but ineffective against methicillin-resistant Staphylococci), saprophytic Staphylococci, Streptococcus pneumoniae (except penicillin-resistant strains), chemical

This product is suitable for the following infections caused by sensitive bacteria: 1. Upper respiratory tract infections: for example: ear, nose and throat infections, including acute otitis media, sinusitis, tonsillitis and pharyngitis; 2. Lower respiratory tract infections: for example: community-acquired pneumonia, acute exacerbation of chronic bronchitis; 3. Simple urinary tract infections: for example: cystitis; 4. Simple skin and skin soft tissue infections: folliculitis (including purulent acne), furuncle, carbuncle, erysipelas, cellulitis, lymphangiitis (nodular) inflammation, suppurative paronychia, subcutaneous abscess, sweat glanditis, clustered acne, and combined infection of sebaceous cysts; 5. Acute simple gonococcal urethritis and cervicitis, and perianal inflammation caused by Neisseria gonorrhoeae.

Usage: Oral administration. This product should be taken after meals. Dosage: Adults: Upper respiratory tract infections including acute otitis media, sinusitis, tonsillitis and pharyngitis, 100 mg (1 tablet), twice a day, for a course of 5-10 days. Lower respiratory tract infections: acute exacerbation of chronic bronchitis, 200 mg (2 tablets), twice a day, for a course of 10 days. Acute community-acquired pneumonia, 200 mg (2 tablets), twice a day, for a course of 14 days. Simple urinary tract infection, 100 mg (1 tablet), twice a day, for a course of 7 days. Acute simple gonorrhea, a single dose of 200 mg (2 tablets). Skin and skin soft tissue infections, 400 mg (4 tablets), twice a day, for a course of 14 days. Children: Acute otitis media 10 mg/kg once a day, or 5 mg/kg twice a day for 40 days.

1. Patients allergic to penicillin or β-lactam antibiotics are contraindicated. 2. Patients allergic to cefpodoxime are contraindicated.

Antacids or H2 receptor antagonists can reduce its absorption and lower its peak plasma concentration; probenecid can increase its plasma concentration level.

Keep away from light, tightly closed, in a cool place.

API